• YAKHAK HOEJI
• /
• v.46 no.3
• /
• pp.168-173
• /
• 2002

The physicochemical properties of aloesin, which has been recently found to reduce renal toxicity induced by cis-platin, were studied including solubility, partition coefficient ( $P_{c}$ ), osmolality, and stability. The solubility of aloesin was about 500 mg/mι, and the $P_{c}$ value for n-octanol/water was 1.01 $\pm$ 0.03. The degradation of aloesin followed the pseudo-first-order kinetics and was dependent on temperature, pH and ionic strength. From the pH-rate profile, the optimal pH was found to be 2.0~3.0. Some metal ions increased the degradation rate in the rank order of M $n^{2+}$ ＞ F $e^{3+}$ ＞ C $u^{2+}$ ＞ F $e^{2+}$. On the other hand, other metal ions such as B $i^{3+}$, $Ba^{2+}$, Z $n^{2+}$, N $i^{2+}$, $Co^{2+}$ and $Mg^{2+}$ did not show the unfavorable effects. After autoclaving, aloesin contents remaining were 81.8~98.8% of initial concentrations depending on pH. The most stable pH was 3.98 in the autoclaving. Osmolality increased linearly as concentration increased.sed.creased.sed.

• Archives of Pharmacal Research
• /
• v.26 no.7
• /
• pp.526-531
• /
• 2003

KR-31378 is a new drug candidate intended for the use in the prevention of ischemia-reperfusion damage. The objective of this preformulation study was to determine the physicochemical properties of KR-31378. The n-octanol to water partition coefficients of KR-31378 were 0.0504 at pH 3 and 0.8874 at pH 10. Accelerated stability of KR-31378 in solution and solid state was studied at 5, 40, $60^{\circ}C$. The stability testing indicated that the t90 for the drug in solid was estimated to be 2 years and 128.6 days at $25^{\circ}C$, while the that in aquesou solution was 68.6 days at $25^{\circ}C$. The KR-31378 was also found to be unstable under the relative humidity of 76%, probably because of the hygroscopic nature of the drug. In order to study compatibility of KR-31378 with typical excipients, potential change in differential scanning calorimetry spectrum was studied in 1:1 binary mixtures of KR-31378 and Aerosil, Avicel, Eudragit, lactose, PEG, talc, CMC, PVP, starch. As a result, CMC, PVP, and starch were found to be incompatible with KR-31378, indicating the addition of these excipients may complicate the manufacturing of the formulation for the drug. Particle size distribution of KR-31378 powder was in the size range of 9-93 $\mu$ m with the mean particle size of 37.9 $\mu$ m. The flowability of KR-31378 was apparently inadequate, indicating the granulation may be necessary for the processing of the drug to solid dosage forms. Crystallization of the drug with a number of organic solvents did not lead a crystalline polymorphism. In addition, dissolution of the drug from the powder was adequately rapid at $37^{\circ}C$ in water.

• Journal of Pharmaceutical Investigation
• /
• v.41 no.4
• /
• pp.227-232
• /
• 2011

Alnus japonica has been known to exert antioxidative, anti-inflammatory, anti-cancer and immune response inhibitory effects. The aim of this study was to figure out the characteristics of extracts obtained with different extraction solvent such as water, 100% ethanol, 70% ethanol or 70% methanol because characteristic components such as oregonin and hirsutanone extracted from Alnus japonica might be essential for the biological activity. For this purpose, oregonin and hirsutanon of four extracts, index ingredient of Alnus japonica, were analyzed with HPLC and physicochemical studies such as SEM, particle size and zeta potential were conducted. In cell cytotoxicity study, extract of water showed the highest cytotoxicity among four extracts. In case of oregonin, 70% MeOH and water extracts showed high contents and in case of hirsutanone, all extracts showed similar contents except 70% EtOH extracts. The extract of 70% MeOH from Alnus japonica for both oregonin and hirsutanone appeared to have the highest content. Both oregonin and hirsutanone extracted from Alnus japonica using 70% methanol showed stability in pH 1.2.

• Archives of Pharmacal Research
• /
• v.26 no.12
• /
• pp.1002-1008
• /
• 2003

Ferulic acid (3-methoxy, 4-hydroxy cinnamic acid) is a flavoid component possessing antioxidant property. The compound is currently under development as a new drug candidate for the treatment of the dementia. The objective of this preformulation study was to determine the physicochemical properties of ferulic acid. The n-octanol to water partition coefficients of ferulic acid were 0.375 and 0.489 at the pHs of 3 and 10, respectively. Accelerated stability study for ferulic acid indicated that the t 90 value for the drug was estimated to be 459 days at $25^{\circ}C$. Ferulic acid was also found to be unstable under the relative humidity of more than 76%, probably because of the hygroscopic nature of the drug. In order to study compatibility of ferulic acid with typical excipients, potential change in differential scanning calorimetry spectrum was studied in 1: 1 binary mixtures of ferulic acid and typical pharmaceutical excipients (e.g., Aerosil, Avicel, CMC, Eudragit, lactose, PEG, PVP, starch and talc). Avicel, CMC, PVP and starch were found to be incompatible with ferulic acid, indicating the addition of these excipients may complicate the manufacturing of the formulation for the drug. Particle size distribution of ferulic acid powder was in the size range of 10-190 $\mu$m with the mean particle size of 61 $\mu$m. The flowability of ferulic acid was apparently inadequate, indicating the granulation may be necessary for the processing of the drug to solid dosage forms. Two polymorphic forms were obtained by recrystallization from various solvents used in formulation. New polymorphic form of ferulic acid, Form II, was obtained by recrystallization from 1,4-dioxane. The equilibrium solubility for Form I was approximately twice of that for Form II. The dissolution rate of Form II was higher than that of Form I in the early phase (<6 min). Therefore, these physicochemical information has to be taken in the consideration for the formulation of ferulic acid.

• Journal of Pharmaceutical Investigation
• /
• v.24 no.1
• /
• pp.33-40
• /
• 1994

In order to develop a broad-spectrum veterinary anthelmintic, a combined preparation of nitroxynil and levamisole was formulated for subcutaneous injection. The preformulation studies on solubilization, physicochemical stability and toxicity of combined preparation were performed. The combined preparation of nitroxynil-N-ethylglucamine and levamisole base could be solubilized up to 50.3%(w/v) of active ingredient concentration in propylene glycol/water system. Injectable solutions were most stable at $4^{\circ}C$. Local toxicities such as flare and edema were not shown when the usual dose of the combined preparation was injected subcutaneously to the rats.

• Journal of Pharmaceutical Investigation
• /
• v.13 no.3
• /
• pp.115-125
• /
• 1983

제제설계란 제형의 설계 및 그에 따른 처방설정(formulation)을 의미하며 경험적인 제제방법 및 그 기술측면에서의 제제화는 주악 및 첨가물의 종류와 배합비율의 설정등 비교적 단순한 내용을 의미하지만 의약품은 실제적으로 인체에 적용되므로 치료설계상의 연구와 생물약제학적 검토에 의한 유효정과 안전성을 발휘할 수 있도록 설계가 되어야 한다. 또한 약물의 효력은 체내 특정부위에 특정농도의 약물분포가 필요하고, 일정시간 지속되는 것이 요구되므로 약용량도 중요하지만 약물투여 후의 흡수, 체내이행, 대사, 배설등의 상태를 파악하고 이에 미치는 부형제의 영향도 검토하여야 한다. 제제물리학적 측면에서 품질보증을 위하여 preformulation단계에서 주약의 물성검토, 첨가제의 사용량, interaction 및 혼합순서 등과 처방설정 단계에서 제제화에 사용되는 기계장치의 특성 및 능력, 제제화 후의 포장용기 및 포장상태에서의 안정성 등도 면밀히 검토하여야한다. 제제설계란 단순한 dosage form의 design만이 아니고 유효성이 높고, 부작용이 적은 제제를 합리적으로 만드는 기술과 정보의 종합관리로 scale up과정에서 원료, 기계장치, 제조방법, 작업자 등에 의한 품질변동 요인을 극소화하고, 공정의 초기단계에서 즉시 조정될 수 있는 종합관리 system이 필요하다.

• Journal of Pharmaceutical Investigation
• /
• v.14 no.2
• /
• pp.55-61
• /
• 1984

This investigation was designed to determine the release of fenbufen from suppositories and their bioavailability in rabbits. Suppositories containing fenbufen were made by the fusion method with Witepsol H-15, Wecobee and PEG 1540 base. Displacement value, weight variation, content uniformity, melting point and melting time were determined for preformulation of the fenbufen suppositories. The release rates were determined with the KP dissolution apparatus and with cellophane tube dialysis device and were increased in order of PEG 1540, Witespol H-15 and Wecobee. The bioavailabilities of fenbufen after rectal administration were also increased in order of PEG 1540, Witespol H-15 and Wecobee.

• Biomolecules & Therapeutics
• /
• v.8 no.4
• /
• pp.332-337
• /
• 2000

Physicochemical properties of aspalatone (acetylsalicylic acid maltol ester, AM), which has been recently found to have an antithrombotic effect, were studied in terms of solubility, dissolution, partition coefficient (Pc) and stability. The solubility of AM at 37$^{\circ}C$ was about 1.2 mg/ml and the P$_{c}$ value for n-octanol/water and chloroform/water was 11.4 and 382.6, respectively. Dissolution rates of AM at pH 1.2 and 6.8 were more than 80% within 30 min. The degradation of AM followed apparent first-order kinetics, and was dependent on temperature, pH and ionic strength. From the pH-rate profile, the optimal pH was found to be at around 4.0. Half-lives at pH 1.2 and 6.8 were 33.5 and 44.4 hr, respectively. The degradation rate of AM at pH 1.2 was somewhat faster than that of aspirin, but at pH 7.0, the degradation rate of AM was slower than that of aspirin.n.

• Analytical Science and Technology
• /
• v.34 no.2
• /
• pp.46-55
• /
• 2021

Evaluation of drug-excipient compatibility is one of the basic steps in the preformulation of pharmaceutical dosage forms. Some reactive excipients have been known so far which may cause stability problems for drug molecules in pharmaceutical dosage forms. The aim of this study was to evaluate drugexcipient compatibility of gliclazide with some common pharmaceutical excipients, known for their ability to incorporate in drug-excipient interactions. Binary mixtures were prepared using lactose, magnesium stearate, polyvinylpyrrolidone, sodium starch glycolate, polyethylene glycol 2000 and dicalcium phosphate. Based on the results; gliclazide was incompatible with all tested excipients; but not with dicalcium phosphate. DSC (Differential Scanning Calorimetry) results were in accordance with HPLC (High Pressure liquid chromatography) data and were more predictive than FTIR (Fourier Transform Infrared Spectroscopy). Drug and reactive excipients incompatibility was fully discussed and documented. It is advisable to avoid incompatible excipients or carefully monitor the drug stability when incorporating such excipients in final formulation designs.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 2001.11a
• /
• pp.88-88
• /
• 2001

The effects of pH and temperature on the degradation of prokidn in various buffered aqueous solutions(pH 1.32~9.66) and temperatures (35, 45 and 6$0^{\circ}C$ were investigated. The effect of ionic strength on the degradation of prokidin was also measured by varying ionic strength (0.0466~1.5) at pH 1.35 and 45$^{\circ}C$ The effect of metal ions on the degradation of prokidin at pH 7.35 and 3.98 was observed. The degradation of prokidin followed the pseudo- first- order kinetics. The degradation rate of prokidin showed pH-dependent and temperature-dependent patterns. Prokidin was very stable at the pH below 3.95, where half-lives at 35, 45 and 6$0^{\circ}C$were 294, 206 and 107 day, respectively. However, it degraded very rapidly at pH above 6.49; the half-lives at 35, 45 and 6$0^{\circ}C$were 60, 25 and 13 day, respectively. As ionic strength increased, the degradation rate of prokidin increased. Some metal ions increased the degradation rate in the rank order of Mn > Fe > Cu >Fe On the other hand. other metal ions such as Bi, Ba. Zn, Ni, Co did not show unfavorable effect.